TNSN99129A1 - Formulations intranasales de mesylate de sildenafil et procede pour leur preparation - Google Patents

Formulations intranasales de mesylate de sildenafil et procede pour leur preparation

Info

Publication number
TNSN99129A1
TNSN99129A1 TNTNSN99129A TNSN99129A TNSN99129A1 TN SN99129 A1 TNSN99129 A1 TN SN99129A1 TN TNSN99129 A TNTNSN99129 A TN TNSN99129A TN SN99129 A TNSN99129 A TN SN99129A TN SN99129 A1 TNSN99129 A1 TN SN99129A1
Authority
TN
Tunisia
Prior art keywords
intranasal formulations
sildenafil mesylate
preparation
intranasal
sildenafil
Prior art date
Application number
TNTNSN99129A
Other languages
English (en)
Inventor
Billotte Anne
James Dunn Peter
Thomas Henry Brian
Vallance Marshall Peter
Jayne Woods Joanne
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9813452.1A external-priority patent/GB9813452D0/en
Priority claimed from GBGB9820837.4A external-priority patent/GB9820837D0/en
Priority claimed from GBGB9903177.5A external-priority patent/GB9903177D0/en
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of TNSN99129A1 publication Critical patent/TNSN99129A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE LE MESYLATE DE SILDENAFIL AINSI QUE LE MONO OU DIHYDRATE CRISTALLIN DE MESYLATE DE SILDENAFIL, ET DES FORMULATIONS INTRANASALES LE CONTENANT. LADITE FORMULATION INTRANASALE EST SOUS FORME D'UNE SOLUTION AQUEUSE OU SOUS FORME DE POUDRE. APPLICATION : UTILISATION DE CES FORMULATIONS INTRANASALES POUR LE TRAITEMENT D'UN DISFONCTIONNEMENT DE L'ERECTION MASCULINE OU DE TROUBLES SEXUELS FEMININS.
TNTNSN99129A 1998-06-22 1999-06-21 Formulations intranasales de mesylate de sildenafil et procede pour leur preparation TNSN99129A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9813452.1A GB9813452D0 (en) 1998-06-22 1998-06-22 Pharmaceutical formulations
GBGB9820837.4A GB9820837D0 (en) 1998-09-24 1998-09-24 Pharmaceutical formulations
GBGB9903177.5A GB9903177D0 (en) 1999-02-13 1999-02-13 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
TNSN99129A1 true TNSN99129A1 (fr) 2005-11-10

Family

ID=27269368

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN99129A TNSN99129A1 (fr) 1998-06-22 1999-06-21 Formulations intranasales de mesylate de sildenafil et procede pour leur preparation

Country Status (40)

Country Link
US (2) US20020040139A1 (fr)
EP (1) EP0967214B1 (fr)
JP (1) JP3263379B2 (fr)
KR (1) KR100345824B1 (fr)
AP (1) AP1178A (fr)
AR (1) AR016993A1 (fr)
AT (1) ATE269866T1 (fr)
AU (1) AU746865B2 (fr)
BG (1) BG64372B1 (fr)
BR (1) BR9903273A (fr)
CA (1) CA2275554C (fr)
CZ (1) CZ294856B6 (fr)
DE (1) DE69918222T2 (fr)
DK (1) DK0967214T3 (fr)
DZ (1) DZ2826A1 (fr)
EA (1) EA001903B1 (fr)
ES (1) ES2221733T3 (fr)
GT (1) GT199900095A (fr)
HN (1) HN1999000096A (fr)
HR (1) HRP990195B1 (fr)
HU (1) HUP9902076A3 (fr)
ID (1) ID23554A (fr)
IL (1) IL130539A0 (fr)
IS (1) IS5085A (fr)
MA (1) MA25089A1 (fr)
MY (1) MY117967A (fr)
NO (1) NO317365B1 (fr)
NZ (1) NZ336382A (fr)
OA (1) OA11069A (fr)
PA (1) PA8476301A1 (fr)
PE (1) PE20000702A1 (fr)
PT (1) PT967214E (fr)
SG (1) SG77246A1 (fr)
SI (1) SI0967214T1 (fr)
SK (1) SK284574B6 (fr)
TN (1) TNSN99129A1 (fr)
TR (1) TR199901444A2 (fr)
TW (1) TWI223598B (fr)
UA (1) UA59385C2 (fr)
YU (1) YU29699A (fr)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200591B1 (en) 1998-06-25 2001-03-13 Anwar A. Hussain Method of administration of sildenafil to produce instantaneous response for the treatment of erectile dysfunction
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
CA2391968A1 (fr) * 1999-11-18 2001-05-25 Natco Pharma Limited Composition pharmaceutique amelioree pour traiter la dyserection masculine
KR20010016165A (ko) * 2000-11-16 2001-03-05 정순학 성기능 장애 치료를 위한 피부에 적용하는 제제
DE10118306A1 (de) 2001-04-12 2002-10-17 Bayer Ag Imidazotriazinonhaltige Zusammensetzungen zur nasalen Applikation
DE10118305A1 (de) * 2001-04-12 2002-10-17 Bayer Ag Zusammensetzungen zur nasalen Applikation
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
WO2002094219A2 (fr) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Administration par voie pulmonaire de medicaments contre les troubles de l'erection
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US6737042B2 (en) 2001-05-24 2004-05-18 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
DE10248601B4 (de) * 2002-10-17 2006-05-24 Goldstein, Naum, Dr.habil.nat. Pharmazeutisches Mittel zur endonasalen Applikation bei der Behandlung von Krankheiten und Störungen des zentralen Nervensystems
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
US7138107B2 (en) * 2003-02-18 2006-11-21 Compellis Pharmaceuticals Inhibition of olfactory neurosensory function to treat eating disorders and obesity
WO2004073729A1 (fr) * 2003-02-21 2004-09-02 Translational Research Ltd. Compositions destinees a l'administration nasale d'un medicament
EP1607117A4 (fr) 2003-03-27 2007-10-24 Bioactis Ltd Applicateur de medicament en poudre pour cavite nasale
AR043880A1 (es) * 2003-04-22 2005-08-17 Solvay Pharm Gmbh Mesilato acido de 4-(4.trans-hidroxiciclohexil) amino-2-fenil-7h-pirrolo (2,3-d) pirimidina y sus formas polimorfas
EP1625333A1 (fr) 2003-05-21 2006-02-15 Alexza Pharmaceuticals, Inc. Unite de chauffage autonome et unite de fourniture de medicament faisant appel a cette unite de chauffage
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
WO2006016530A1 (fr) * 2004-08-10 2006-02-16 Translational Research, Ltd. Composition transnasale dont l’action est immédiate et l’absorbabilité est élevée
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8524274B2 (en) 2004-10-18 2013-09-03 Polymun Scientific Immunbiologische Forschung Gmbh Liposomal composition comprising an active ingredient for relaxing smooth muscle, the production of this composition and the therapeutic use thereof
CA2600636A1 (fr) * 2005-03-09 2006-09-14 Boehringer Ingelheim International Gmbh Nouvelles compositions pharmaceutiques a base d'anticholinergiques et d'inhibiteurs de pde 5
ME01609B (me) 2005-04-19 2014-09-20 Takeda Gmbh Roflumilast za liječenje pulmonarne hipertenzije
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
ES2308750T3 (es) * 2005-08-29 2008-12-01 Teva Pharmaceutical Industries Ltd Tadalafil en particulas solidas que presenta una distribucion de particulas bimodal.
GB0526283D0 (en) * 2005-12-23 2006-02-01 Givaudan Sa Compositions
GB0606234D0 (en) * 2006-03-29 2006-05-10 Pliva Istrazivanje I Razvoj D Pharmaceutically acceptable salts and polymorphic forms
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008078730A1 (fr) 2006-12-26 2008-07-03 Translational Research, Ltd. Préparation pour administration transnasale
US8293489B2 (en) 2007-01-31 2012-10-23 Henkin Robert I Methods for detection of biological substances
ES2594867T3 (es) 2007-03-09 2016-12-23 Alexza Pharmaceuticals, Inc. Unidad de calentamiento para usar en un dispositivo de administración de fármaco
DE102008004893A1 (de) * 2008-01-17 2009-07-23 Add Technologies Ltd. Trägerpellets, Verfahren zu deren Herstellung und deren Verwendung
WO2009098697A1 (fr) * 2008-02-08 2009-08-13 Dexxon Ltd. Formes pharmaceutiques de modafinil et de sildénafil
US20090258865A1 (en) * 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
AU2008357475B2 (en) 2008-06-04 2012-11-01 Colgate-Palmolive Company Oral care implement with cavitation system
WO2009152344A2 (fr) * 2008-06-11 2009-12-17 Comgenrx, Inc. Polythérapie à base d’inhibiteurs de phosphodiestérases
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
JP2011001317A (ja) * 2009-06-19 2011-01-06 Fumakilla Ltd 鼻用洗浄剤
WO2011013003A2 (fr) * 2009-07-31 2011-02-03 Shin Nippon Biomedical Laboratories, Ltd. Granisétron pour administration intranasale et applicateur nasal
US9993433B2 (en) 2010-05-10 2018-06-12 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
CN107737100A (zh) 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 苯二氮卓组合物的投与
CN102952138B (zh) * 2011-08-17 2016-07-06 上海特化医药科技有限公司 一种吡唑并嘧啶酮化合物的盐、多晶型物及其药物组合物、制备方法和应用
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
WO2014055801A1 (fr) * 2012-10-05 2014-04-10 Henkin Robert I Inhibiteurs de la phosphodiestérase destinés à traiter des troubles du goût et de l'odorat
CA2881144A1 (fr) * 2012-11-09 2014-05-09 Purdue Pharma Compositions pharmaceutiques comprenant de l'hydromorphone et de la naloxone
RU2536425C2 (ru) * 2013-01-17 2014-12-20 Общество с ограниченной ответственностью "Фармамед" Фармацевтическая композиция, содержащая силденафил цитрат, и способ ее приготовления
WO2014143453A1 (fr) * 2013-03-15 2014-09-18 Henkin Robert I Traitement faisaint intervenir un inhibiteur de la phosphodiestérase
US9814710B2 (en) 2013-11-13 2017-11-14 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015126944A1 (fr) 2014-02-18 2015-08-27 Henkin Robert I Procédés et compositions permettant de diagnostiquer et de traiter une perte et/ou une distorsion du goût ou de l'odorat
NO2723977T3 (fr) 2014-03-19 2018-03-10
CA2994709A1 (fr) * 2015-08-03 2017-02-09 Synergistic Therapeutics, Llc Gel therapeutique pour dysfonctionnement sexuel
WO2018076074A1 (fr) * 2016-10-31 2018-05-03 Suda Ltd Administration de principes actifs par voie muqueuse
CA3055094A1 (fr) * 2017-03-02 2018-09-07 Dutch Renewable Energy B.V. Administration intranasale de substances physiologiquement actives
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
US11464778B2 (en) * 2017-12-26 2022-10-11 Liqmeds Worldwide Limited Liquid oral formulations for sildenafil
JP6941224B2 (ja) 2018-02-06 2021-09-29 イージス セラピューティクス，エルエルシー 疾患の処置のための鼻腔内エピネフリン製剤及び方法
WO2019200427A1 (fr) * 2018-04-16 2019-10-24 Barista Mist Pty Ltd Compositions de caféine et procédés d'utilisation
SE542968C2 (en) * 2018-10-26 2020-09-22 Lindahl Anders Treatment of osteoarthritis
CA3187753A1 (fr) * 2020-07-29 2022-02-03 Lido Ventures Llc Appareil, systeme et procede pour faciliter le traitement intranasal d'un patient

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE69600784T2 (de) * 1995-11-20 1999-04-08 Lilly Co Eli Proteinkinase-C-Inhibitor
EP0992240A4 (fr) * 1997-05-29 2003-04-16 Mochida Pharm Co Ltd Agent therapeutique destine a traiter l'anerection
CA2312839C (fr) * 1997-12-02 2008-01-15 Lisbeth Illum Compositions pour administration nasale
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase

Also Published As

Publication number Publication date
HU9902076D0 (en) 1999-08-30
AP1178A (en) 2003-06-30
UA59385C2 (uk) 2003-09-15
IS5085A (is) 1999-12-23
HRP990195A2 (en) 2000-02-29
NO317365B1 (no) 2004-10-18
US20020040139A1 (en) 2002-04-04
SG77246A1 (en) 2000-12-19
NZ336382A (en) 1999-11-29
JP2000034232A (ja) 2000-02-02
CZ294856B6 (cs) 2005-03-16
AU746865B2 (en) 2002-05-02
CZ9902257A3 (cs) 2000-11-15
JP3263379B2 (ja) 2002-03-04
NO993051D0 (no) 1999-06-21
EA199900487A2 (ru) 1999-12-29
EA199900487A3 (ru) 2000-04-24
AR016993A1 (es) 2001-08-01
TR199901444A2 (xx) 2000-01-21
CA2275554A1 (fr) 1999-12-22
SK81999A3 (en) 2001-01-18
OA11069A (en) 2002-03-13
KR20000006310A (ko) 2000-01-25
HUP9902076A3 (en) 2002-03-28
EP0967214A1 (fr) 1999-12-29
SK284574B6 (sk) 2005-06-02
DK0967214T3 (da) 2004-09-27
PE20000702A1 (es) 2000-08-16
US20030158206A1 (en) 2003-08-21
KR100345824B1 (ko) 2002-07-24
YU29699A (sh) 2003-02-28
DE69918222D1 (de) 2004-07-29
HUP9902076A2 (hu) 2000-05-28
AU3579499A (en) 2000-01-06
GT199900095A (es) 2000-12-13
ATE269866T1 (de) 2004-07-15
TWI223598B (en) 2004-11-11
NO993051L (no) 1999-12-23
BG64372B1 (bg) 2004-12-30
PT967214E (pt) 2004-08-31
EA001903B1 (ru) 2001-10-22
EP0967214B1 (fr) 2004-06-23
HN1999000096A (es) 2000-12-03
AP9901585A0 (en) 1999-06-30
ID23554A (id) 2000-05-04
IL130539A0 (en) 2000-06-01
BR9903273A (pt) 2000-05-09
DZ2826A1 (fr) 2003-12-01
PA8476301A1 (es) 2000-09-29
MA25089A1 (fr) 2000-12-31
MY117967A (en) 2004-08-30
SI0967214T1 (en) 2004-10-31
CA2275554C (fr) 2003-06-03
BG103510A (en) 2000-01-31
DE69918222T2 (de) 2005-07-28
ES2221733T3 (es) 2005-01-01
HRP990195B1 (en) 2003-04-30

Similar Documents

Publication Publication Date Title
TNSN99129A1 (fr) Formulations intranasales de mesylate de sildenafil et procede pour leur preparation
TNSN99125A1 (fr) Pyrrolo(2,3-d) pyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97192A1 (fr) Derives de pyrimidine bicycliques condenses, procede pour leur preparation et compositions pharmaceutiques les contenant.
EE9900465A (et) Uued ühendid
TNSN99126A1 (fr) Pyrrolopyrimidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99073A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99106A1 (fr) Derives d'isothiazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99155A1 (fr) 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN00199A1 (fr) PYRAZOLO [4,3-d] PYRIMIDINES-7-ONES PHARMACEUTIQUEMENT ACTIVES, LEUR PREPARATION ET MEDICAMENTS LES CONTENANT
TNSN99169A1 (fr) Derives de 4,4-biarylpiperidine nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN97144A1 (fr) Derives 6,6-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99171A1 (fr) 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98216A1 (fr) Derives d'acide hydrauxamique, compositions pharmaceutiques les contenant et procede pour leur preparation
TNSN99236A1 (fr) Derives bicycliques substitues nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98112A1 (fr) Composes dipeptidiques
TNSN00065A1 (fr) Derives nouveaux de pyrimidine inhibiteurs de sorbitol- deshydrogenase, leur procede de preparation et compositions pharmaceutiques les contenant.
TNSN98154A1 (fr) Derives de 2-aminopyridine nouveaux et compositions pharmaceutiques les contenant
TNSN97145A1 (fr) Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98024A1 (fr) 2-amino-6-(2-substitue-4-phenoxy)-substitue-pyridines, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99147A1 (fr) Procede d'emulsification
TNSN98194A1 (fr) Derives nouveaux de 6-o-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN98104A1 (fr) Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN99031A1 (fr) Composes heterocycliques nouveaux inhibiteurs de romatases, procede pour leur preparation et compositions pharmaceutiques les contenant